AU3490300A - Dopamine agonists in combination with nitric oxide donors, compositions and methods of use - Google Patents

Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Info

Publication number
AU3490300A
AU3490300A AU34903/00A AU3490300A AU3490300A AU 3490300 A AU3490300 A AU 3490300A AU 34903/00 A AU34903/00 A AU 34903/00A AU 3490300 A AU3490300 A AU 3490300A AU 3490300 A AU3490300 A AU 3490300A
Authority
AU
Australia
Prior art keywords
compositions
methods
combination
nitric oxide
dopamine agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34903/00A
Inventor
David S. Garvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitromed Inc
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Publication of AU3490300A publication Critical patent/AU3490300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU34903/00A 1999-03-12 2000-03-10 Dopamine agonists in combination with nitric oxide donors, compositions and methods of use Abandoned AU3490300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12392099P 1999-03-12 1999-03-12
US60123920 1999-03-12
PCT/US2000/003709 WO2000054773A1 (en) 1999-03-12 2000-03-10 Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Publications (1)

Publication Number Publication Date
AU3490300A true AU3490300A (en) 2000-10-04

Family

ID=22411703

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34903/00A Abandoned AU3490300A (en) 1999-03-12 2000-03-10 Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Country Status (2)

Country Link
AU (1) AU3490300A (en)
WO (1) WO2000054773A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
DE19938825A1 (en) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Active ingredient combination with clonidine
DE19938823A1 (en) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol
CN1554341A (en) * 2000-04-21 2004-12-15 �������Ŷ���Լ��������˾ Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
ITMI20011308A1 (en) 2001-06-21 2002-12-21 Nicox Sa DRUGS FOR CHRONIC PAIN
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
ATE450187T1 (en) * 2001-12-06 2009-12-15 Univ Duke PREVENTION OF SKIN FLAPE NECROSIS IN PLASTIC SURGERY
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
ITMI20022658A1 (en) 2002-12-17 2004-06-18 Nicox Sa DRUGS FOR CHRONIC PAIN.
US20050256186A1 (en) * 2004-03-05 2005-11-17 Fumie Morishige Prevention of and countermeasures against mitochondrial disease
ES2429443T3 (en) * 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Transdermal supply of beneficial substances by means of an environment of high ionic strength
EP2420241A1 (en) * 2004-04-19 2012-02-22 Strategic Science & Technologies, LLC Transdermal delivery of beneficial substances effected by a hostile biophysical environment
AU2012201048B2 (en) * 2004-04-19 2013-06-06 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
ITMI20041855A1 (en) * 2004-09-29 2004-12-29 Polichem Sa PHARMACEUTICAL COMPOSITIONS OF ALFA-DIHYDROERGOCRIPTINE FOR TRANSDERMAL AND-OR TRANSMUCOUS USE.
CN102438587B (en) 2009-05-19 2015-08-19 神经层有限公司 For the compositions of dopa decarboxylase inhibitor continuous administration
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US8604081B2 (en) 2009-06-24 2013-12-10 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
AU2011330757B2 (en) 2010-11-15 2016-05-26 Neuroderm Ltd Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
CN103442723A (en) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 Systems and methods for treatment of allergies and other indications
PT2658551T (en) 2010-12-29 2020-07-24 Strategic Science & Tech Llc Treatment of erectile dysfunction and other indications
NZ703341A (en) 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
DK3116475T3 (en) 2014-03-13 2020-12-07 Neuroderm Ltd DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN105434439B (en) * 2015-11-11 2018-07-24 温州医科大学 A kind of partial agonist of d2 dopamine receptor inhibits the application on near-sighted drug and its application method preparing
US10945980B2 (en) 2016-06-21 2021-03-16 The University Of Newcastle Treatment for myopia
EP3616723B1 (en) * 2018-07-18 2024-08-07 Wenzhou Medical University Use of nicotinic acid or prazosin for treating myopia
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
ATE312609T1 (en) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc SUBLINGUAL COMPOSITION CONTAINING APOMORPHINE FOR THE DIAGNOSTICS OF FUNCTIONAL IMPOTENCY

Also Published As

Publication number Publication date
WO2000054773A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
AU3490300A (en) Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
EP1497268A4 (en) Nitric oxide donors, compositions and methods of use
GB2353523B (en) Methods and compositions for use in cementing in cold environments
AU2003243984A1 (en) Hydrogenated copolymer and composition thereof
AU2003271498A8 (en) Coolant solutions and compositions comprising the sameitle
AU2002358754A1 (en) Polyisobutene and polyisobutene derivatives for use in lubricant compositions
HUP9900152A3 (en) Anti-microbial cosmetical composition based on alcohol and its use
HK1082194A1 (en) Composition comprising echovirus ev1 and its use ev1
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
AU2003230715A1 (en) In vivo use of glutathionone s-transferase activated nitric oxide donors
AU2001230902A1 (en) Slow-release insect-repellent composition and uses
IL150219A0 (en) Mulch composition and methods for the preparation and use thereof
AU2002347614A1 (en) Antioxidant combination composition and use thereof
IL144710A0 (en) Methods and compositions for use in perfusion applications
EE04490B1 (en) The compound, its method of preparation and its use in medicine
HUP0203844A3 (en) Compound with growth hormone releasing properties, pharmaceutical composition containing it and its use
AU2003251394A1 (en) An oral composition with insulin-like activities and methods of use
HUP0301558A3 (en) Cleaning composition containing an antioxidant and its use
AU2003260241A1 (en) Buguzhi agent and composition and methods of preparing and administering the same
GB0026467D0 (en) Compound, composition and use
AU4996100A (en) (s,r) formoterol methods and compositions
AU2001265025A1 (en) Fluorinated copolymer surfactants and use thereof in aerosol compositions
HUP0203721A3 (en) Novel hormonal composition and the use thereof
AU2002361337A1 (en) Amphoteric polysaccharide, composition and use
AU7598000A (en) Antimicrobial topical composition and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase